Godl K - Search Results

1

Evaluation of kinase inhibitor selectivity by chemical proteomics.

Daub H, Godl K, Brehmer D, Klebl B, Müller G. Daub H, et al. Among authors: godl k. Assay Drug Dev Technol. 2004 Apr;2(2):215-24. doi: 10.1089/154065804323056558. Assay Drug Dev Technol. 2004. PMID: 15165517 Review.

2

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H. Godl K, et al. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15434-9. doi: 10.1073/pnas.2535024100. Epub 2003 Dec 10. Proc Natl Acad Sci U S A. 2003. PMID: 14668439 Free PMC article.

3

Proteomic analysis of kinase inhibitor selectivity and function.

Godl K, Daub H. Godl K, et al. Cell Cycle. 2004 Apr;3(4):393-5. Epub 2004 Apr 1. Cell Cycle. 2004. PMID: 14752275

4

Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors.

Brehmer D, Godl K, Zech B, Wissing J, Daub H. Brehmer D, et al. Among authors: godl k. Mol Cell Proteomics. 2004 May;3(5):490-500. doi: 10.1074/mcp.M300139-MCP200. Epub 2004 Feb 9. Mol Cell Proteomics. 2004. PMID: 14769951 Free article.

5

Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.

Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Müller S, Daub H. Wissing J, et al. Among authors: godl k. Mol Cell Proteomics. 2004 Dec;3(12):1181-93. doi: 10.1074/mcp.M400124-MCP200. Epub 2004 Oct 8. Mol Cell Proteomics. 2004. PMID: 15475568 Free article.

6

Cellular targets of gefitinib.

Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J, Daub H. Brehmer D, et al. Among authors: godl k. Cancer Res. 2005 Jan 15;65(2):379-82. Cancer Res. 2005. PMID: 15695376

7

Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.

Godl K, Gruss OJ, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orfi L, Horváth Z, Kéri G, Müller S, Cotten M, Ullrich A, Daub H. Godl K, et al. Cancer Res. 2005 Aug 1;65(15):6919-26. doi: 10.1158/0008-5472.CAN-05-0574. Cancer Res. 2005. PMID: 16061676 Free article.

8

Exploiting features of adenovirus replication to support mammalian kinase production.

Cotten M, Stegmueller K, Eickhoff J, Hanke M, Herzberger K, Herget T, Choidas A, Daub H, Godl K. Cotten M, et al. Among authors: godl k. Nucleic Acids Res. 2003 Nov 1;31(21):e128. doi: 10.1093/nar/gng128. Nucleic Acids Res. 2003. PMID: 14576328 Free PMC article.

9

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib.

Schaab C, Oppermann FS, Klammer M, Pfeifer H, Tebbe A, Oellerich T, Krauter J, Levis M, Perl AE, Daub H, Steffen B, Godl K, Serve H. Schaab C, et al. Among authors: godl k. Leukemia. 2014 Mar;28(3):716-9. doi: 10.1038/leu.2013.347. Epub 2013 Nov 19. Leukemia. 2014. PMID: 24247654 Free PMC article. No abstract available.

10

Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G. Conradt L, et al. Among authors: godl k. Neoplasia. 2011 Nov;13(11):1026-34. doi: 10.1593/neo.111016. Neoplasia. 2011. PMID: 22131878 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page